Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Journal of Pharmaceutical Sciences|January 14, 2015
The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technologyRinpei Niwa, Mitsuo SatohMabs|January 13, 2010
Production of therapeutic antibodies with controlled fucosylationNaoko Yamane-Ohnuki, Mitsuo SatohDrug Design, Development and Therapy|November 19, 2009
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCAkito Natsume, Rinpei Niwa, Mitsuo SatohExpert Opinion on Biological Therapy|October 20, 2006
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodiesMitsuo Satoh, Shigeru Iida, Kenya ShitaraMethods in Molecular Biology (Clifton, N.J.)|March 29, 2008
Biallelic gene knockouts in Chinese hamster ovary cellsNaoko Yamane-Ohnuki, Kazuya Yamano, Mitsuo SatohLeukemia Research|December 22, 2009
Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophilsTomoaki Nakagawa, Akito Natsume, Mitsuo Satoh, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 29, 2026
[Selenium deficiency-associated macrocytic anemia in elderly patients receiving parenteral nutrition]Kenichi Sawada, Takao Obara, Motooki Keimatsu, et al.Cytokine|September 3, 2017
Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5Tsutomu Yanagibashi, Mitsuo Satoh, Yoshinori Nagai, et al.Journal of Proteome Research|August 5, 2010
A peptidomics strategy for discovering endogenous bioactive peptidesKazuki Sasaki, Noriyuki Takahashi, Mitsuo Satoh, et al.Cancer Science|September 18, 2009
Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activityAkito Natsume, Yukiko Shimizu-Yokoyama, Mitsuo Satoh, et al.Pageof 4